drugset / Trial / NCT03966066
Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin Intervention
RandomizedParallel-groupOpen-labelTreatment
Summary
According to their compliance, the children were divided into two groups: low dose erythromycin treated group (erythromycin 3-5mg/kg.d orally for 6 months) and non-erythromycin treatment group. The quality of life score and acute exacerbation were evaluated during the observation period (6 months) and one year after the withdrawal of Erythromycin.The pulmonary imaging changes and the degree of deterioration in pulmonary function were compared between the two groups.
Timeline
- Start
- 2019-08
- Primary completion
- 2020-07
- Completion
- 2020-07
Publications
- Background Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65 Suppl 1:i1-58. doi: 10.1136/thx.2010.136119.
- Background Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002 Sep 28;360(9338):978-84. doi: 10.1016/s0140-6736(02)11081-6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erythromycin | Small molecule | 3 mg/kg | Oral |
| Subject | Erythromycin | Small molecule | 5 mg/kg | Oral |